• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Update: Annual Changes to the Nasdaq-100® Index

    12/12/23 6:00:00 PM ET
    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Investment Bankers/Brokers/Service
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NDAQ alert in real time by email

    NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced an update to the annual reconstitution of the Nasdaq-100 Index® (NASDAQ:NDX). Per the announcement by Pfizer Inc. (NYSE:PFE), the pending acquisition of Seagen, Inc. (NASDAQ:SGEN) is expected to close on December 14, 2023. As a result, Take-Two Interactive Software, Inc. (NASDAQ:TTWO), will be added to the Nasdaq-100 Index® and Seagen, Inc. will be removed as part of the annual reconstitution, which will become effective prior to market open on Monday, December 18, 2023.

    The other constituent changes from the initial announcement by Nasdaq on Friday, December 8, 2023, will remain the same.

    Information

    For information about the company being added to the Nasdaq-100 Index® per this update, please visit the company website: Take-Two Interactive Software, Inc. – https://www.take2games.com/.

    About Nasdaq Global Indexes

    Nasdaq Global Indexes has been creating innovative, market-leading, transparent indexes since 1971. Today, our index offering spans geographies and asset classes and includes diverse families such as the Dividend and Income (includes Dividend Achievers), Nasdaq Dorsey Wright, Fixed Income (includes BulletShares®), Global Equity, Green Economy, Nordic, and Commodity indexes. We continuously offer new opportunities for financial product sponsors across a wide spectrum of investable products and for asset managers to measure risk and performance. Nasdaq also provides exchange listing, custom index, and design solutions to financial organizations worldwide.

    About Nasdaq

    Nasdaq (NASDAQ:NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financial system. We aspire to deliver world-leading platforms that improve the liquidity, transparency, and integrity of the global economy. Our diverse offering of data, analytics, software, exchange capabilities, and client-centric services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions, and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at www.nasdaq.com.

    The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The Nasdaq OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq's proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

    - NDAQG -

    Media Relations ContactsInvestor Relations Contact  
    Name: Camille StaffordName: Index Client Services  
    Email: [email protected]

    Email  [email protected]  
      
    Name: Jennifer Lawson 
    Email: [email protected] 
      


    Primary Logo

    Get the next $NDAQ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NDAQ
    $PFE
    $SGEN
    $TTWO

    CompanyDatePrice TargetRatingAnalyst
    Pfizer Inc.
    $PFE
    4/22/2025$24.00Neutral
    Cantor Fitzgerald
    Nasdaq Inc.
    $NDAQ
    4/17/2025$91.00Neutral → Buy
    Redburn Atlantic
    Nasdaq Inc.
    $NDAQ
    4/8/2025$74.00Overweight → Equal-Weight
    Morgan Stanley
    Take-Two Interactive Software Inc.
    $TTWO
    2/19/2025$250.00Buy
    DA Davidson
    Take-Two Interactive Software Inc.
    $TTWO
    1/27/2025$175.00 → $230.00Buy → Neutral
    UBS
    Take-Two Interactive Software Inc.
    $TTWO
    1/27/2025$175.00 → $230.00Neutral → Buy
    UBS
    Nasdaq Inc.
    $NDAQ
    1/8/2025$80.00 → $98.00Hold → Buy
    Deutsche Bank
    Take-Two Interactive Software Inc.
    $TTWO
    12/11/2024$200.00 → $225.00Buy
    Citigroup
    More analyst ratings

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Leadership Updates

    Live Leadership Updates

    See more
    • Shopify Inc to Join the Nasdaq-100 Index® Beginning May 19, 2025

      NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Shopify Inc. (NASDAQ:SHOP), will become a component of the Nasdaq-100 Index® (NASDAQ:NDX®) and the Nasdaq-100 Equal Weighted™ Index (NASDAQ:NDXE) prior to market open on Monday, May 19, 2025. Shopify Inc. will replace MongoDB, Inc. (NASDAQ:MDB) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted™ Index. MongoDB, Inc. will also be removed from the Nasdaq-100 Tech Sector™ Index (NASDAQ:NDXT), the Nasdaq-100 Technology Sector Market-Cap Weighted™ Index (NDXTMC™), the Nasdaq-100 Technology Sector Adjusted Market-Cap Weighted™ Index (NDXT10™), the Nasdaq-100 ESG™ Index (NASDAQ:NDXESG), the Nasdaq-100

      5/9/25 8:00:00 PM ET
      $MDB
      $NDAQ
      $SHOP
      Computer Software: Prepackaged Software
      Technology
      Investment Bankers/Brokers/Service
      Finance
    • Dexcom Appoints Jon Coleman as Chief Commercial Officer

      DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

      3/25/25 4:05:00 PM ET
      $DXCM
      $MASI
      $PFE
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Biotechnology: Pharmaceutical Preparations
    • Nasdaq Appoints Brandis DeSimone as New Head of East Coast Listings

      The appointment strengthens Nasdaq's commitment to supporting companies throughout their corporate lifecycle Nasdaq is the exchange of choice for new listings and exchange transfers in the US, raising $22.97 Billion in IPO proceeds across 180 listings in 2024 and celebrating over 500 transfers to Nasdaq since 2005 NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced the appointment of Brandis DeSimone as Senior Vice President, Head of East Coast Listings. Under the recently established regional operational structure, this appointment further strengthens Nasdaq's commitment to supporting companies throughout their corporate lifecycle and deepening client rel

      3/3/25 10:40:42 AM ET
      $NDAQ
      Investment Bankers/Brokers/Service
      Finance

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 25, 2024 - FDA Roundup: October 25, 2024

      For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

      10/25/24 2:48:21 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for HYMPAVZI issued to PFIZER INC

      Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

      10/15/24 2:57:27 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

      For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

      10/11/24 2:12:15 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

      Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutationVepdegestrant was generally well tolerated, with few discontinuations and low rates of gastrointestinal-related adverse events Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancerData to be featured in a late-breaking oral presentation at ASCO and simultaneously published in the New England Journal of MedicineArvinas will host a conference call t

      5/31/25 8:00:50 AM ET
      $ARVN
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pfizer's BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

      Pivotal results from the Phase 3 BREAKWATER trial showed 51% risk reduction in death compared to standard-of-care treatment BRAFTOVI combination regimen also demonstrated 47% risk reduction in disease progression or death compared to standard-of-care treatment, meeting the trial's dual primary endpoint of progression-free survival First and only combination regimen with targeted therapy to improve survival outcomes for treatment-naïve patients with BRAF V600E-mutant metastatic colorectal cancer Pfizer Inc. (NYSE:PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combinat

      5/30/25 8:00:00 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nasdaq Executives to Present at Upcoming Investor Conferences

      NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) will be presenting at the following conferences in June with webcasts available at Nasdaq's Investor Relations website: ir.nasdaq.com/events.cfm. Who:Adena Friedman, Chair and CEO, NasdaqWhat:Piper Sandler Global Exchange & Trading ConferenceWhen:Thursday, June 5, 20252:30 PM ET  Who:Tal Cohen, President, NasdaqWhat:Morgan Stanley US Financials ConferenceWhen:Tuesday, June 10, 20259:45 AM ET   About Nasdaq Nasdaq (NASDAQ:NDAQ) is a global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financ

      5/28/25 4:05:00 PM ET
      $NDAQ
      Investment Bankers/Brokers/Service
      Finance

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

      SC 13G/A - NASDAQ, INC. (0001120193) (Subject)

      11/12/24 3:53:01 PM ET
      $NDAQ
      Investment Bankers/Brokers/Service
      Finance
    • SEC Form SC 13G filed by Nasdaq Inc.

      SC 13G - NASDAQ, INC. (0001120193) (Subject)

      11/8/24 10:52:39 AM ET
      $NDAQ
      Investment Bankers/Brokers/Service
      Finance
    • Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

      SC 13G/A - NASDAQ, INC. (0001120193) (Subject)

      11/4/24 1:18:47 PM ET
      $NDAQ
      Investment Bankers/Brokers/Service
      Finance

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

      4 - PFIZER INC (0000078003) (Issuer)

      2/14/25 5:16:36 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Zollar Alfred W bought $203,970 worth of shares (2,542 units at $80.24), increasing direct ownership by 5% to 49,293 units (SEC Form 4)

      4 - NASDAQ, INC. (0001120193) (Issuer)

      11/14/24 4:29:16 PM ET
      $NDAQ
      Investment Bankers/Brokers/Service
      Finance
    • Director Gottlieb Scott bought $28,240 worth of shares (1,000 units at $28.24), increasing direct ownership by 11% to 10,000 units (SEC Form 4)

      4 - PFIZER INC (0000078003) (Issuer)

      10/31/24 4:06:54 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Pfizer with a new price target

      Cantor Fitzgerald initiated coverage of Pfizer with a rating of Neutral and set a new price target of $24.00

      4/22/25 8:03:45 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NASDAQ upgraded by Redburn Atlantic with a new price target

      Redburn Atlantic upgraded NASDAQ from Neutral to Buy and set a new price target of $91.00

      4/17/25 8:27:31 AM ET
      $NDAQ
      Investment Bankers/Brokers/Service
      Finance
    • NASDAQ downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded NASDAQ from Overweight to Equal-Weight and set a new price target of $74.00

      4/8/25 9:21:41 AM ET
      $NDAQ
      Investment Bankers/Brokers/Service
      Finance

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Financials

    Live finance-specific insights

    See more
    • Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

      Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutationVepdegestrant was generally well tolerated, with few discontinuations and low rates of gastrointestinal-related adverse events Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancerData to be featured in a late-breaking oral presentation at ASCO and simultaneously published in the New England Journal of MedicineArvinas will host a conference call t

      5/31/25 8:00:50 AM ET
      $ARVN
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Take-Two Interactive Software, Inc. Reports Results for Fourth Quarter and Fiscal Year 2025

      $1.58 billion fourth quarter Net Bookings $5.65 billion fiscal year 2025 Net Bookings Initial outlook for fiscal 2026 includes Net Bookings of $5.9 to $6.0 billion Take-Two Interactive Software, Inc. (NASDAQ:TTWO) today reported results for the fourth quarter and fiscal year 2025, ended March 31, 2025. For further information, please see the fourth quarter and fiscal 2025 results slide deck posted to the Company's investor relations website at take2games.com/ir. CEO Comments "We achieved outstanding results in our 2025 Fiscal Year, with each of our labels contributing meaningfully to our performance. Our Fiscal 2026 outlook reflects continuing positive momentum, with Net Bookings guida

      5/15/25 4:05:00 PM ET
      $TTWO
      Computer Software: Prepackaged Software
      Technology
    • Take-Two Interactive Software, Inc. Reiterates Expectations to Achieve Sequential Increases in, and Record Levels of, Net Bookings in Fiscal 2026 and 2027

      Rockstar Games announces release date for Grand Theft Auto VI of May 26, 2026 Company to report its fourth quarter and Fiscal 2025 results on May 15, 2025 Take-Two Interactive Software, Inc. (NASDAQ:TTWO) today reiterated its expectations that the Company will achieve sequential increases in, and record levels of, Net Bookings in Fiscal 2026 and 2027. In addition, Take-Two's wholly-owned label, Rockstar Games, has announced that Grand Theft Auto VI, which was expected to launch in Fall of 2025, is now planned for release on May 26, 2026, during the Company's Fiscal Year 2027. "We support fully Rockstar Games taking additional time to realize their creative vision for Grand Theft Auto VI,

      5/2/25 7:30:00 AM ET
      $TTWO
      Computer Software: Prepackaged Software
      Technology

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    SEC Filings

    See more
    • SEC Form SD filed by Pfizer Inc.

      SD - PFIZER INC (0000078003) (Filer)

      5/30/25 1:07:24 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Nasdaq Inc.

      DEFA14A - NASDAQ, INC. (0001120193) (Filer)

      5/28/25 4:10:54 PM ET
      $NDAQ
      Investment Bankers/Brokers/Service
      Finance
    • SEC Form 8-K filed by Take-Two Interactive Software Inc.

      8-K - TAKE TWO INTERACTIVE SOFTWARE INC (0000946581) (Filer)

      5/22/25 4:15:10 PM ET
      $TTWO
      Computer Software: Prepackaged Software
      Technology

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Dornemann Michael was granted 262 shares, increasing direct ownership by 1% to 21,694 units (SEC Form 4)

      4 - TAKE TWO INTERACTIVE SOFTWARE INC (0000946581) (Issuer)

      5/30/25 4:38:38 PM ET
      $TTWO
      Computer Software: Prepackaged Software
      Technology
    • Director Moses Jon J was granted 262 shares, increasing direct ownership by 1% to 23,647 units (SEC Form 4)

      4 - TAKE TWO INTERACTIVE SOFTWARE INC (0000946581) (Issuer)

      5/30/25 4:34:47 PM ET
      $TTWO
      Computer Software: Prepackaged Software
      Technology
    • Director Sheresky Michael was granted 262 shares, increasing direct ownership by 0.40% to 65,140 units (SEC Form 4)

      4 - TAKE TWO INTERACTIVE SOFTWARE INC (0000946581) (Issuer)

      5/30/25 4:31:54 PM ET
      $TTWO
      Computer Software: Prepackaged Software
      Technology